Project Grant R01CA309833
Award Date 8/18/26
Completion Date 7/31/30
Dollars Obligated $347K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Cancer Institute awarded New York University School of Medicine $466,125 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate whether incretin mimetics reduce the risk of development and progression of multiple myeloma and its precursor conditions, monoclonal gammopathy of undetermined significance (MGUS). The research employs two murine models of disease to determine whether weight loss alone and treatment with incretin mimetics reduces disease...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $2,498,737 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify mechanisms of malignant transformation in monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) and develop therapies for early interception of progression to multiple myeloma. The award funds three integrated research projects and two supporting cores. Project 1 discovers, models,...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded Mayo Clinic $558,016 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate accelerated biological aging and immunosenescence as drivers of racial disparities in monoclonal gammopathy of undetermined significance (MGUS). The funded research examines why multiple myeloma and its precursor condition MGUS occur at disproportionately high rates and younger average ages in individuals of African ancestry. The project tests the...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Missouri System $486,426 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to explore niche-leukemic stem cell interactions and evaluate niche-directed leukemia treatments. The research aims to unravel how minimal residual leukemic stem cells survive within the bone marrow microenvironment, called the niche, which drives therapeutic...
- The National Cancer Institute awarded The Washington University $646,785 for a Project Grant (R01CA308205) on August 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds research into mechanisms supporting growth and survival of tumors driven by constitutively active GNAQ/11 mutations, which occur across a diverse group of rare cancers responsible for approximately thirty percent of annual cancer deaths in the United States. The project investigates how...
- The National Cancer Institute awarded The Washington University $498,290 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate epigenetic regulation of premalignant states in cutaneous squamous cell carcinoma. The funded research defines the causes and consequences of KDM6A mislocalization in skin cancer through two primary aims. Aim 1 involves exome sequencing of banked human tumors to identify genomic correlates of KDM6A mislocalization, in...
- The National Cancer Institute awarded The Washington University $155,500 for research identifying and characterizing mutation-induced alternative splicing events in cancer using multi-omics data, with an award date of June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The project aims to discover mutation-induced alternative splicing events, understand their functional relevance, and identify neoantigens arising from these events to advance cancer immunotherapy. The research...
- The National Cancer Institute awarded The Washington University $637,394 on August 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop positron emission tomography imaging using a radiotracer (64Cu-DOTA-ECL1I) that quantifies C-C motif chemokine receptor 2 (CCR2) expression in head and neck squamous cell carcinoma patients. The project will establish CCR2-PET as a prognostic biomarker to predict tumor activity, disease recurrence, and response to...
- The National Cancer Institute awarded The Washington University Office of Sponsored Research Services $643,286 on August 1, 2026, to investigate DNA methylation epimutations in acute myeloid leukemia under the Cancer Biology Research program (CFDA 93.396). The research investigates allele-specific DNA methylation epimutations as clonal events that arise in normal cells and may be selected for during leukemogenesis. The project uses primary human acute myeloid leukemia samples, normal...